Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Arbutus Biopharma	CymaBay Therapeutics	Oncternal Therapeutics	CorMedix	ProQR Therapeutics
Symbol	NASDAQ:ABUS	NASDAQ:CBAY	NASDAQ:ONCT	NYSEAMERICAN:CRMD	NASDAQ:PRQR
Price Information
Current Price	$2.78	$3.98	$5.35	$7.92	$5.83
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.4	1.6	1.7	1.2	1.4
Analysis Score	3.4	3.5	4.5	3.5	3.5
Community Score	2.8	3.0	3.3	2.5	2.5
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	1.7	0.0	0.0	0.8
Earnings & Valuation Score	0.6	0.0	0.6	0.0	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$6.50	$11.77	$15.20	$19.30	$30.86
% Upside from Price Target	133.81% upside	195.71% upside	184.11% upside	143.69% upside	429.28% upside
Trade Information
Market Cap	$285.16 million	$290.96 million	$295.69 million	$318.64 million	$310.77 million
Beta	3.15	1.45	1.66	2.71	0.73
Average Volume	2,271,815	1,066,296	1,623,037	1,063,908	2,862,839
Sales & Book Value
Annual Revenue	$6.01 million	N/A	$2.42 million	$280,000.00	N/A
Price / Sales	44.56	N/A	109.13	1,075.54	N/A
Cashflow	N/A	N/A	N/A	$0.21 per share	N/A
Price / Cash	N/A	N/A	N/A	37.85	N/A
Book Value	($1.00) per share	$2.71 per share	$0.93 per share	$0.92 per share	$2.11 per share
Price / Book	-2.78	N/A	5.75	8.61	N/A
Profitability
Net Income	$-153,720,000.00	$-102,810,000.00	$-34,190,000.00	$-16,430,000.00	$-63,560,000.00
EPS	($1.62)	($1.46)	($1.56)	($0.89)	($1.55)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-1,163.48%	N/A	-746.10%	-10,214.42%	N/A
Return on Equity (ROE)	N/A	-34.86%	-150.58%	-86.52%	-62.92%
Return on Assets (ROA)	-59.66%	-32.23%	-91.87%	-70.16%	-47.69%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	N/A	0.24%
Current Ratio	15.94%	15.88%	3.01%	8.45%	8.52%
Quick Ratio	15.94%	15.88%	3.01%	8.40%	8.52%
Ownership Information
Institutional Ownership Percentage	28.44%	84.28%	10.79%	25.91%	55.87%
Insider Ownership Percentage	6.70%	4.00%	10.90%	5.00%	N/A
Miscellaneous
Employees	76	41	12	30	154
Shares Outstanding	96.34 million	68.95 million	49.36 million	38.02 million	50.21 million
Next Earnings Date	8/6/2021 (Estimated)	5/10/2021 (Estimated)	5/6/2021 (Confirmed)	5/10/2021 (Estimated)	5/6/2021 (Estimated)
Optionable	Optionable	Optionable	Not Optionable	Optionable	Optionable

Source	Headline
	ProQR: Q1 Earnings Snapshot sfgate.com - May 6 at 8:30 AM
	ProQR Therapeutics Stock Is Trading Higher On Antisense Oligonucleotide Development Pact finance.yahoo.com - May 4 at 1:33 PM
	ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target finance.yahoo.com - May 4 at 8:33 AM
	ProQR Therapeutics (NASDAQ:PRQR) Short Interest Update americanbankingnews.com - May 3 at 4:42 PM
	ProQR Therapeutics (NASDAQ:PRQR) Now Covered by Analysts at Stifel Nicolaus americanbankingnews.com - May 3 at 8:40 AM
	ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Up 48.1% YTD, Predicting What To Expect Ahead marketingsentinel.com - May 1 at 9:16 AM
	ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 finance.yahoo.com - April 23 at 8:25 AM
	For Risk-Tolerant Investors, ProQR Therapeutics N.V. (NASDAQ:PRQR) Is Worth A Shot marketingsentinel.com - April 22 at 1:03 PM
	ProQR Announces Participation in Upcoming Kempen Life Sciences Conference finance.yahoo.com - April 22 at 8:03 AM
	ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by Brokerages americanbankingnews.com - April 19 at 10:50 AM
	ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 finance.yahoo.com - April 13 at 8:28 PM
	Why should you add ProQR Therapeutics N.V. (PRQR) to your portfolio? marketingsentinel.com - April 12 at 1:03 PM
	Shark Bites: Taking Advantage of Weak Biotechnology Action realmoney.thestreet.com - April 8 at 1:46 PM
	ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares finance.yahoo.com - April 5 at 6:50 PM
	ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and ... apnews.com - April 2 at 6:44 PM
	ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares finance.yahoo.com - March 30 at 11:13 PM
	ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares finance.yahoo.com - March 30 at 6:13 PM
	Analyst Lights Up Over ProQR Blindness Trial Results finance.yahoo.com - March 26 at 5:32 PM
	ProQR Shares Gain 62% on Stellar Results in Phase 1/2 Usher Syndrome Trial streetwisereports.com - March 25 at 8:57 PM
	Why ProQR Therapeutics's Stock is Up During Today's Session benzinga.com - March 25 at 3:57 PM
	PRQR Stock: 7 Things to Know About High-Flying ProQR Therapeutics feedproxy.google.com - March 25 at 2:52 PM
	ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to ... apnews.com - March 25 at 10:53 AM
	Market Analysts see ProQR Therapeutics N.V. [PRQR] gaining to $22. Time to buy? dbtnews.com - March 25 at 10:53 AM
	ProQR’s RNA therapy on track to pivotal tests in rare, inherited form of vision loss medcitynews.com - March 24 at 7:53 PM
	Why ProQR Therapeutics Stock Is Popping Today fool.com - March 24 at 1:46 PM

Date	Company	Brokerage	Action
3/10/2021	Arbutus Biopharma	B. Riley	Lower Price Target
3/10/2021	Arbutus Biopharma	HC Wainwright	Reiterated Rating
2/25/2021	Arbutus Biopharma	Jefferies Financial Group	Initiated Coverage
11/16/2020	Arbutus Biopharma	Chardan Capital	Reiterated Rating
7/27/2020	Arbutus Biopharma	JMP Securities	Initiated Coverage
7/24/2020	Arbutus Biopharma	Robert W. Baird	Downgrade
5/19/2020	Arbutus Biopharma	Wedbush	Upgrade
10/4/2019	Arbutus Biopharma	Echelon Wealth Partners	Downgrade
3/31/2021	CymaBay Therapeutics	Cantor Fitzgerald	Lower Price Target
3/9/2021	CymaBay Therapeutics	Piper Sandler	Reiterated Rating
11/30/2020	CymaBay Therapeutics	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target
11/30/2020	CymaBay Therapeutics	Smith Barney Citigroup	Boost Price Target
11/6/2020	CymaBay Therapeutics	Raymond James	Boost Price Target
11/6/2020	CymaBay Therapeutics	SVB Leerink	Boost Price Target
9/29/2020	CymaBay Therapeutics	Lifesci Capital	Reiterated Rating
9/10/2020	CymaBay Therapeutics	Oppenheimer	Reiterated Rating
8/3/2020	CymaBay Therapeutics	Stifel Nicolaus	Boost Price Target
3/30/2021	Oncternal Therapeutics	Brookline Capital Management	Reiterated Rating
3/30/2021	Oncternal Therapeutics	Brookline Capital Acquisition	Initiated Coverage
2/23/2021	Oncternal Therapeutics	Northland Securities	Initiated Coverage
2/17/2021	CorMedix	Needham & Company LLC	Initiated Coverage
9/21/2020	CorMedix	Truist	Initiated Coverage
12/6/2018	CorMedix	Roth Capital	Reiterated Rating
8/11/2019	ProQR Therapeutics	Royal Bank of Canada	Reiterated Rating

(Data available from 5/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources